In BioVie’s Phase 2 Trial, Bezisterim is Safe and Reduces Neurological Symptoms of Long Covid

BioVie, a pharmaceutical company developing treatments for neurological diseases, recently announced results from its phase 2 clinical trial ADDRESS-LC (NCT06847191), of the new drug Bezisterim. Evidence suggests that Bezisterim lowers […]
FDA Patient-Focused Drug Development Public Meeting for Long Covid

The US Food and Drug Administration (FDA) is hosting a virtual public meeting on Patient-Focused Drug Development for Long Covid on Tuesday, April 25th, 2023, from 10 a.m. to 4:00 p.m. […]
FDA to Host Patient-Focused Drug Development Public Meeting for Long Covid

The US Food and Drug Administration (FDA) is hosting a virtual public meeting on Patient-Focused Drug Development for Long Covid on Tuesday, April 25th, 2023, from 10 a.m. to 4:00 p.m. […]